Cidara Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

Cidara Therapeutics

02/11/2023 22:05

* Cidara Therapeutics Inc  CDTX.OQ  reported a quarterly
adjusted
loss of 9 cents​​ per share for the quarter ended in September,
lower than the same quarter last year, when the company reported
EPS of 17 cents.  The mean expectation of four analysts for the
quarter was for a loss of 16 cents per share. Wall Street
expected results to range from -20 cents to -11 cents per share.
    * Revenue fell 72.4% to $11.25 million from a year ago;
analysts
expected $8.14 million. 
    * Cidara Therapeutics Inc's reported EPS for the quarter was
a
loss of 9 cents​.
    * The company reported a quarterly loss of $8.17 million.
    * Cidara Therapeutics Inc shares had fallen by 14.7% this
quarter and gained 6.2% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 74.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Cidara
Therapeutics Inc is $5.50 
This summary was machine generated from LSEG data November 2 at
10:05 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2023      -0.16          -0.09          Beat
 Jun. 30 2023      -0.13          -0.14          Missed
 Mar. 31 2023      -0.04          0.03           Beat
 Dec. 31 2022      -0.17          -0.19          Missed